HCW Biologics doses first patient in Phase 1 trial of HCW9302 for alopecia areata

HCW Biologics Inc.

First patient dosed at Ohio State University Wexner Medical Center in multi-center first-in-human Phase 1 trial.
HCW9302 is a subcutaneous IL-2 fusion molecule designed to expand Treg cells, built on the TOBI platform.
Trial plans to enroll up to 30 patients; primary objectives are safety and determination of recommended Phase 2 dose.
Secondary endpoints include disease response and effects on Treg cell proliferation; expansion into other autoimmune and inflammatory conditions is planned.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.